GlassScriptPhysician profile
Kelly C Allen
NPI 1033549605
$5,411.98
in general payments reported to CMS, 2019-2025
21 companies · $2,055 in 2025
The $2,055 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $378 · 2022: $766 · 2023: $1,043 · 2024: $1,170 · 2025: $2,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,157 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,156.71 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $860.46 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $767.54 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Corium, LLC | $561.35 | 2022-2025 | Azstarys |
| Abbvie INC. | $528.27 | 2022-2025 | |
| Axsome Therapeutics, INC. | $478.18 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $430.51 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $405.85 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $378.84 | 2021-2025 | Invega Sustenna |
| Lundbeck LLC | $266.03 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.11 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $141.92 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $116.11 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $94.04 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $60.64 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $57.64 | 2021-2024 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $20.58 | 2022 | |
| Ironshore Pharmaceuticals INC. | $19.18 | 2024 | |
| Vanda Pharmaceuticals INC. | $17.25 | 2024 | Fanapt |
| Eisai INC. | $14.49 | 2021 | |
| Tris Pharma INC | $14.15 | 2021 | |
| Neos Therapeutics, LP | $12.84 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.